Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.76 Billion CNY | -15.28% |
| 2022 | 13.89 Billion CNY | 29.21% |
| 2021 | 10.75 Billion CNY | 61.93% |
| 2020 | 6.63 Billion CNY | 51.05% |
| 2019 | 4.39 Billion CNY | 11.07% |
| 2018 | 3.95 Billion CNY | 19.16% |
| 2017 | 3.32 Billion CNY | 24.5% |
| 2016 | 2.66 Billion CNY | 33.22% |
| 2015 | 2 Billion CNY | 43.83% |
| 2014 | 1.39 Billion CNY | 61.77% |
| 2013 | 860.63 Million CNY | 36.84% |
| 2012 | 628.94 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 10.97 Billion CNY | -2.86% |
| 2024 Q1 | 11.6 Billion CNY | -1.41% |
| 2024 Q2 | 11.3 Billion CNY | -2.59% |
| 2023 Q4 | 11.76 Billion CNY | -3.25% |
| 2023 FY | 11.76 Billion CNY | -15.28% |
| 2023 Q1 | 13.4 Billion CNY | -3.47% |
| 2023 Q2 | 12.23 Billion CNY | -8.79% |
| 2023 Q3 | 12.16 Billion CNY | -0.56% |
| 2022 Q3 | 13.91 Billion CNY | 1.24% |
| 2022 Q2 | 13.74 Billion CNY | 9.38% |
| 2022 Q1 | 12.56 Billion CNY | 16.87% |
| 2022 FY | 13.89 Billion CNY | 29.21% |
| 2022 Q4 | 13.89 Billion CNY | -0.16% |
| 2021 Q1 | 7.92 Billion CNY | 19.32% |
| 2021 Q3 | 9.58 Billion CNY | 10.95% |
| 2021 Q4 | 10.75 Billion CNY | 12.15% |
| 2021 FY | 10.75 Billion CNY | 61.93% |
| 2021 Q2 | 8.63 Billion CNY | 9.06% |
| 2020 Q4 | 6.63 Billion CNY | 5.14% |
| 2020 FY | 6.63 Billion CNY | 51.05% |
| 2020 Q1 | 4.48 Billion CNY | 1.99% |
| 2020 Q2 | 5.53 Billion CNY | 23.41% |
| 2020 Q3 | 6.31 Billion CNY | 14.14% |
| 2019 FY | 4.39 Billion CNY | 11.07% |
| 2019 Q4 | 4.39 Billion CNY | 0.14% |
| 2019 Q3 | 4.38 Billion CNY | 3.94% |
| 2019 Q2 | 4.22 Billion CNY | 3.36% |
| 2019 Q1 | 4.08 Billion CNY | 3.25% |
| 2018 Q1 | 3.32 Billion CNY | 0.16% |
| 2018 Q2 | 3.69 Billion CNY | 10.98% |
| 2018 FY | 3.95 Billion CNY | 19.16% |
| 2018 Q3 | 3.92 Billion CNY | 6.29% |
| 2018 Q4 | 3.95 Billion CNY | 0.85% |
| 2017 Q3 | 3.43 Billion CNY | 20.97% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 3.32 Billion CNY | 24.5% |
| 2017 Q2 | 2.83 Billion CNY | 0.0% |
| 2017 Q4 | 3.32 Billion CNY | -3.24% |
| 2016 Q4 | 2.66 Billion CNY | 0.0% |
| 2016 FY | 2.66 Billion CNY | 33.22% |
| 2015 Q3 | 1.96 Billion CNY | 0.0% |
| 2015 FY | 2 Billion CNY | 43.83% |
| 2015 Q4 | 2 Billion CNY | 1.94% |
| 2014 FY | 1.39 Billion CNY | 61.77% |
| 2013 FY | 860.63 Million CNY | 36.84% |
| 2012 FY | 628.94 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 14.3 Billion CNY | 17.766% |
| Joinn Laboratories(China)Co.,Ltd. | 10.02 Billion CNY | -17.358% |
| WuXi AppTec Co., Ltd. | 74.26 Billion CNY | 84.155% |
| Autobio Diagnostics Co., Ltd. | 11.55 Billion CNY | -1.849% |
| Thalys Medical Technology Group Inc. | 3.34 Billion CNY | -252.137% |
| Chemclin Diagnostics Co., Ltd. | 1.82 Billion CNY | -546.376% |